In addition, the Committee was concerned that the company had not demonstrated that it would have been able to monitor the quality of the medicine to an acceptable level.
Lisaks ei olnud komitee rahul sellega, et ettevõte ei tõendanud, et ta suudab jälgida ravimi kvaliteeti vastuvõetaval tasemel.